Loading clinical trials...
Loading clinical trials...
Controllability and Real Life Efficacy of Bonviva 3 mg iv Quarterly vs. Oral Alendronate Generics
This observational study will assess the compliance and persistence of patients, real life efficacy and safety of intravenously quarterly administered 3 mg ibandronate \[Bonviva/Boniva\] in comparison to oral alendronate generics in female patients with post-menopausal osteoporosis. The anticipated time of assessment is 12 months. The target sample size is 5000-7000 patients.
Age
55 - No limit years
Sex
FEMALE
Healthy Volunteers
No
Marburg, Germany
Start Date
April 1, 2010
Primary Completion Date
December 1, 2011
Completion Date
December 1, 2011
Last Updated
November 2, 2016
6,054
ACTUAL participants
alendronate
DRUG
ibandronate [Bonviva/Boniva]
DRUG
Lead Sponsor
Hoffmann-La Roche
NCT05010590
NCT07329543
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05060380